Markus Renschler MD - 22 Feb 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
President and CEO, Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 16:02:53 UTC
Previous filing
17 Jun 2021
Next filing
23 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Award $0 +106,200 $0.000000 106,200 22 Feb 2022 Common Stock 106,200 $5.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.